Axsome Therapeutics (AXSM) – Research Analysts’ Recent Ratings Changes

Several analysts have recently updated their ratings and price targets for Axsome Therapeutics (NASDAQ: AXSM):

• 1/29/2026 – Axsome Therapeutics had its “buy” rating reaffirmed by analysts at TD Cowen.
• 1/28/2026 – Axsome Therapeutics had its price target raised by analysts at Leerink Partners from $150.00 to $205.00. They now have an “outperform” rating on the stock.
• 1/21/2026 – Axsome Therapeutics had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 1/21/2026 – Axsome Therapeutics had its price target raised by analysts at Royal Bank Of Canada from $212.00 to $219.00. They now have an “outperform” rating on the stock.
• 1/20/2026 – Axsome Therapeutics had its price target raised by analysts at HC Wainwright from $200.00 to $260.00. They now have a “buy” rating on the stock.
• 1/16/2026 – Axsome Therapeutics had its price target raised by analysts at Piper Sandler from $148.00 to $223.00. They now have an “overweight” rating on the stock.
• 1/14/2026 – Axsome Therapeutics had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald.
• 1/13/2026 – Axsome Therapeutics was given a new $209.00 price target on by analysts at Robert W. Baird.
• 1/13/2026 – Axsome Therapeutics had its price target raised by analysts at Wells Fargo & Company from $157.00 to $193.00. They now have an “overweight” rating on the stock.
• 1/8/2026 – Axsome Therapeutics was downgraded by analysts at Morgan Stanley from an “overweight” rating to a “reduce” rating.
• 1/8/2026 – Axsome Therapeutics had its “equal weight” rating reaffirmed by analysts at Morgan Stanley. They now have a $204.00 price target on the stock, up previously from $196.00.
• 1/6/2026 – Axsome Therapeutics had its price target raised by analysts at UBS Group AG from $163.00 to $248.00. They now have a “buy” rating on the stock.
• 1/5/2026 – Axsome Therapeutics had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $225.00 price target on the stock.
• 1/5/2026 – Axsome Therapeutics had its price target raised by analysts at HC Wainwright from $185.00 to $200.00. They now have a “buy” rating on the stock.
• 1/2/2026 – Axsome Therapeutics had its “buy” rating reaffirmed by analysts at Guggenheim. They now have a $205.00 price target on the stock.
• 12/31/2025 – Axsome Therapeutics was given a new $217.00 price target on by analysts at Mizuho.
• 12/31/2025 – Axsome Therapeutics had its “outperform” rating reaffirmed by analysts at Oppenheimer Holdings, Inc.. They now have a $220.00 price target on the stock.
• 12/31/2025 – Axsome Therapeutics had its “overweight” rating reaffirmed by analysts at Morgan Stanley.
• 12/31/2025 – Axsome Therapeutics had its “buy” rating reaffirmed by analysts at TD Cowen.
• 12/31/2025 – Axsome Therapeutics had its price target raised by analysts at Needham & Company LLC from $154.00 to $169.00. They now have a “buy” rating on the stock.

Insider Activity

In other Axsome Therapeutics news, Director Mark E. Saad sold 37,577 shares of Axsome Therapeutics stock in a transaction dated Wednesday, December 31st. The shares were sold at an average price of $165.18, for a total value of $6,206,968.86. Following the completion of the transaction, the director directly owned 10,002 shares of the company’s stock, valued at approximately $1,652,130.36. The trade was a 78.98% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Ari Maizel sold 7,500 shares of the company’s stock in a transaction that occurred on Wednesday, January 21st. The stock was sold at an average price of $184.44, for a total transaction of $1,383,300.00. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 440,403 shares of company stock valued at $67,191,178 in the last quarter. 22.30% of the stock is owned by company insiders.

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.